STOCK TITAN

LadRx (CYTR) Stock News, Dec 22-31, 2020

CYTR NYSE
Rhea-AI Summary

CytRx Corporation (OTCQB: CYTR) updates on the FDA's review of Orphazyme A/S's NDA for arimoclomol, aimed at treating Niemann-Pick Disease Type C (NPC). The FDA extended the review period by three months, setting a new PDUFA target action date of June 17, 2021. Despite the extension, the NDA holds Priority Review status, which suggests potential for significant therapeutic advancement. Orphazyme has received several designations for arimoclomol and is committed to the drug's approval and subsequent commercialization in both the U.S. and Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
62.90%
Tags
none
-
Rhea-AI Summary

CytRx Corporation (OTCQB: CYTR) congratulated ImmunityBio and NantKwest on their proposed merger, which aims to form a leading company in immunotherapy and cell therapy. CytRx previously out-licensed aldoxorubicin to ImmunityBio in 2017, with potential milestone payments of up to $343 million. The merger is expected to enhance clinical programs, especially the Phase 2 study involving aldoxorubicin for pancreatic cancer. The combined firm will have a vast pipeline of 13 clinical trials across multiple cancer types, potentially transforming treatment options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
62.90%
Tags
none